I reckon the business (or IP) is for sale. They are clearly not on a path to do further internal development with the shedding of technical staff and no real CEO. I think they will struggle to get a buyer given the Ph2 results from competitors in this space:
http://www.proximagen.com/docs/Proximagen%20VAP-1.pdf
http://www.glpg.com/index.php/download_file/view/753/172/
http://www.glpg.com/index.php/download_file/view/822/164/
The current shareprice shows that the market values the IP at approx $11m (market cap less cash at hand)...it cost them about $120m to develop it!
If it makes you feel any better - I also followed the shareholder action group hype and recently sold out with a chunky loss. This is the risk you take with these high risk/high reward stocks. In hindsight, Retirewell were the original "spruikers" of Cbio and had a vested interest in keeping the dream alive as it was linked to their exisiting customer base. In my opinion, the dream is over...and so is an 80c shareprice.
(end note : I still love speculative biotech, so I've doubled-down my investment into PYC)
- Forums
- ASX - By Stock
- mushrooms
I reckon the business (or IP) is for sale. They are clearly not...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CBZ (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online